Improved neuroprotective effects of resveratrol-loaded polysorbate 80-coated poly(lactide) nanoparticles in MPTP-induced Parkinsonism

Nanomedicine

Volumn 10, Issue 7, 2015, Pages 1127-1138

  Da Rocha Lindner, Gabriela ^a   Bonfanti Santos, Danúbia ^b   Colle, Dirleise ^b   Gasnhar Moreira, Eduardo Luiz ^b   Daniel Prediger, Rui ^b   Farina, Marcelo ^b   Khalil, Najeh Maissar ^a   Mara Mainardes, Rubiana ^a  

^a UNIVERSIDADE ESTADUAL DO CENTRO OESTE   (Brazil)

^b FEDERAL UNIVERSITY OF SANTA CATARINA   (Brazil)

Author keywords

antioxidant; nanoparticles; Parkinson's disease; polysorbate 80; resveratrol

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; NANOPARTICLE; POLYLACTIDE; POLYSORBATE 80; RESVERATROL; THIOBARBITURIC ACID REACTIVE SUBSTANCE; TYROSINE 3 MONOOXYGENASE; ANTIOXIDANT; DRUG CARRIER; NEUROPROTECTIVE AGENT; POLYESTER; POLYSORBATE; STILBENE DERIVATIVE;

ADULT; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; COMPARATIVE STUDY; CONTROLLED STUDY; CORPUS STRIATUM; DRUG BIOAVAILABILITY; DRUG DETERMINATION; DRUG EFFECT; DRUG RELEASE; DRUG SYNTHESIS; ENCAPSULATION; EXPERIMENTAL BEHAVIORAL TEST; GROOMING; HABITUATION; LIPID PEROXIDATION; MALE; MEMORY; MOTOR PERFORMANCE; MOUSE; MPTP-INDUCED PARKINSONISM; NEUROCHEMISTRY; NEUROPROTECTION; NONHUMAN; OLFACTORY DISCRIMINATION; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; RECOGNITION; SNIFFING; SOCIAL RECOGNITION TEST; TREATMENT DURATION; WESTERN BLOTTING; ZETA POTENTIAL; ANIMAL; C57BL MOUSE; CHEMISTRY; DOPAMINERGIC NERVE CELL; DRUG EFFECTS; METABOLISM; PARKINSON DISEASE, SECONDARY; PATHOLOGY; PATHOPHYSIOLOGY; SMELLING;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMALS; ANTIOXIDANTS; CORPUS STRIATUM; DOPAMINERGIC NEURONS; DRUG CARRIERS; MALE; MEMORY; MICE; MICE, INBRED C57BL; NEUROPROTECTIVE AGENTS; OLFACTORY PERCEPTION; OXIDATIVE STRESS; PARKINSON DISEASE, SECONDARY; POLYESTERS; POLYSORBATES; STILBENES;

EID: 84929082495     PISSN: 17435889     EISSN: 17486963     Source Type: Journal    
DOI: 10.2217/nnm.14.165     Document Type: Article

References (55)

1. Schapira AH. Neurobiology and treatment of Parkinson's disease. Trends Pharmacol. Sci. 30, 41-47 (2008).
2. Schapira AH, Bezard E, Brotchie J et al. Novel pharmacological targets for the treatment of Parkinson's disease. Nat. Rev. Drug Discov. 5, 845-854 (2006).
3. Chaudhuri KR, Schapira AH. Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment. Lancet Neurol. 8, 464-474 (2009).
4. Jenner P. Oxidative stress in Parkinson's disease. Ann. Neurol. 53, 26-38 (2003).
5. Schieler JL, Liu F, Mirzaei H et al. Effect of oxidative stress on α-synuclein aggregation in Parkinson's disease. Nanomedicine 2, 317 (2006).
6. Henchcliffe C, Beal MF. Mitochondrial biology and oxidative stress in Parkinson disease pathogenesis. Nat. Clin. Pract. Neurol. 4, 600-609 (2008).
7. Alam ZI, Jenner A, Daniel SE et al. Oxidative DNA damage in the parkinsonian brain: an apparent selective increase in 8-hydroxyguanine levels in substantianigra. J. Neurochem. 69, 196-203 (1997).
8. Floor E, Wetzel MG. Increased protein oxidation in human substantia nigra pars compacta in comparison with basal ganglia and prefrontal cortex measured with an improved dinitrophenyl hydrazine assay. J. Neurochem. 70, 268-275 (1998).
9. Allain H, Bentué-Ferrer D, Akwa Y. Disease-modifying drugs and Parkinson's disease. Prog. Neurobiol. 84, 25-39 (2008).
10. Jin H, Kanthasamy A, Ghosh A, Anantharam V, Kalyanaraman B, Kanthasamy AG. Mitochondria-targeted antioxidants for treatment of Parkinson's disease: preclinical and clinical outcomes. Biochim. Biophys. Acta 1842(8), 1282-1294 (2014).
11. Zuo L, Motherwell MS. The impact of reactive oxygen species and genetic mitochondrial mutations in Parkinson's disease. Gene 532, 18-23 (2013).
12. Frozza RL, Bernardi A, Hoppe JB et al. Neuroprotective effects of resveratrol against Aβ administration in rats are improved by lipid-core nanocapsules. Mol. Neurobiol. 47, 1066-1080 (2013).
13. Frozza RL, Bernardi A, Hoppe JB et al. Lipid-core nanocapsules improve the effects of resveratrol against Abetainduced neuroinflammation. J. Biomed. Nanotechnol. 12, 2086-2104 (2013).
14. Kristl J, Teskac K, Caddeo C, Abramovic Z, Šentjurc M. Improvements of cellular stress response on resveratrol in liposomes. Eur. J. Pharm. Biopharm. 73, 253-259 (2009).
15. Lu Z, Cheng B, Hu Y, Zhang Y, Zou G. Complexation of resveratrol with cyclodextrins: solubility and antioxidant activity. Food. Chem. 113, 17-20 (2009).
16. Carrizzo A, Forte M, Damato A et al. Antioxidant effects of resveratrol in cardiovascular, cerebral and metabolic diseases. Food. Chem. Toxicol. 61, 215-226 (2013).
17. He S, Yan X. From resveratrol to its derivatives: new sources of natural antioxidant. Curr. Med. Chem. 20, 1005-1017 (2013).
18. Foti Cuzzola V, Ciurleo R, Giacoppo S, Marino S, Bramanti P. Role of resveratrol and its analogues in the treatment of neurodegenerative diseases: focus on recent discoveries. CNS Neurol. Disord. Drug Targets 10, 849-862 (2011).
19. Pallàs M, Porquet D, Vicente A, Sanfeliu C. Resveratrol: new avenues for a natural compound in neuroprotection. Curr. Pharm. Des. 19, 6726-6731 (2013).
20. Khan MM, Ahmad A, Ishrat T et al. Resveratrol attenuates 6-hydroxydopamine-induced oxidative damage and dopamine depletion in rat model of Parkinson's disease. Brain Res. 1328, 139-151 (2010).
21. Jin F, Wu Q, Lu YF, Gong QH, Shi JS. Neuroprotective effect of resveratrol on 6-OHDA-induced Parkinson's disease in rats. Eur. J. Pharmacol. 600, 78-82 (2008).
22. Lu KT, Ko MC, Chen BY et al. Neuroprotective effects of resveratrol on MPTP-induced neuron loss mediated by free radical scavenging. J. Agric. Food Chem. 56, 6910-6913 (2008).
23. Walle T, Hsieh F, Delegge MK, Oatis JE, Walle K. High absorption but very low bioavailability of oral resveratrol in humans. Drug Metab. Dispos. 32, 1377-1382 (2004).
24. Amri A, Chaumeil JC, Sfar S, Charrueau C. Administration of resveratrol: what formulation solutions to bioavailability limitations? J. Control. Release 158, 182-193 (2012).
25. Khalil NM, do Nascimento TC, Casa DM et al. Pharmacokinetics of curcumin-loaded PLGA and PLGA-PEG blend nanoparticles after oral administration in rats. Colloids Surf. B Biointerfaces 101, 353-360 (2013).
26. Mainardes RM, Khalil NM, Gremião MP. Intranasal delivery of zidovudine by PLA and PLA-PEG blend nanoparticles. Int. J. Pharm. 395, 266-271 (2010).
27. Soppimath KS, Aminabhavi TM, Kulkarni AR, Rudzinski WE. Biodegradable polymeric nanoparticles as drug delivery devices. J. Control. Release 70, 1-20 (2001).
28. Kreuter J, Shamenkov D, Petrov V et al. Apolipoprotein-mediated transport of nanoparticle-bound drugs across the blood-brain barrier. J. Drug Target 10, 317-325 (2002).
29. Petri B, Bootz A, Khalansky A et al. Chemotherapy of brain tumour using doxorubicin bound to surfactant-coated poly(butyl cyanoacrylate) nanoparticles: revisiting the role of surfactants. J. Control. Release 117, 51-58 (2007).
30. Prediger RD, Aguiar AS Jr, Moreira EL et al. The intranasal administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): a new rodent model to test palliative and neuroprotective agents for Parkinson's disease. Curr. Pharm. Des. 17, 489-507 (2011).
31. Prediger RD, Rial D, Medeiros R, Figueiredo CP, Doty RL, Takahashi RN. An intranasal MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) rat model of Parkinson's disease. Ann. NY Acad. Sci. 1170, 629-636 (2009).
32. Prediger RD, Batista LC, Medeiros R, Pandolfo P, Florio JC, Takahashi RN. The risk is in the air: intranasal administration of MPTP to rats reproducing clinical features of Parkinson's disease. Exp. Neurol. 202, 391-403 (2006).
33. Moreira EL, Rial D, Aguiar AS Jr et al. Proanthocyanidinrich fraction from Croton celtidifolius Baill confers neuroprotection in the intranasal 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine rat model of Parkinson's disease. J. Neural Transm. 117, 1337-1351 (2010).
34. Castro AA, Ghisoni K, Latini A, Quevedo J, Tasca CI, Prediger RD. Lithium and valproate prevent olfactory discrimination and short-term memory impairments in the intranasal 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) rat model of Parkinson's disease. Behav. Brain Res. 229, 208-215 (2012).
35. Prediger RD, Aguiar AS Jr, Rojas-Mayorquin AE et al. Single intranasal administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in C57BL/6 mice models early preclinical phase of Parkinson's disease. Neurotox Res. 17, 114-129 (2010).
36. Matheus FC, Aguiar AS Jr, Castro AA et al. Neuroprotective effects of agmatine in mice infused with a single intranasal administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Behav. Brain Res. 235, 263-272 (2012).
37. Lindner GR, Khalil NM, Mainardes RM. Resveratrolloaded polymeric nanoparticles: validation of an HPLC-PDA method to determine the drug entrapment and evaluation of its antioxidant activity. Sci. World J. 2013, 506083 (2013).
38. Prediger RD, Takahashi RN. Modulation of short-term social memory in rats by adenosine A1 and A(2A) receptors. Neurosci. Lett. 376, 160-165 (2005).
39. Dantzer R, Bluthe RM, Koob GF, Le Moal M. Modulation of social memory in male rats by neurohypophyseal peptides. Psychopharmacology 91, 363-368 (1987).
40. Prediger RD, Batista LC, Takahashi RN. Caffeine reverses age-related deficits in olfactory discrimination and social recognition memory in rats. Involvement of adenosine A1 and A2A receptors. Neurobiol. Aging 26, 957-964 (2005).
41. Ohkawa H, Ohishi N, Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal. Biochem. 95, 351-358 (1979).
42. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193, 265-275 (1951).
43. Cho YW, Lee J, Lee SC, Huh KM, Park K. Hydrotropic agents for study of in vitro paclitaxel release from polymeric nanoparticles. J. Control. Release 97, 249-257 (2004).
44. Siepmann J, Peppas NA. Modeling of drug release from delivery systems based on hydroxypropyl methylcellulose (HPMC). Adv. Drug Deliv. Rev. 48, 139-157 (2001).
45. Ritger PL, Peppas NA. A simple equation for description of solute release II. Fickian and anomalous release from swellable devices. J. Control. Release 5, 37-42 (1987).
46. Gilgun-Sherki Y, Melamed E, Offen D. Oxidative stress induced-neurodegenerative diseases: the need for antioxidants that penetrate the blood brain barrier. Neuropharmacol. 40, 959-975 (2001).
47. Wohlfart S, Gelperina S, Kreuter J. Transport of drugs across the blood-brain barrier by nanoparticles. J. Control. Release 20, 264-273 (2012).
48. Doty RL. Olfactory dysfunction in Parkinson disease. Nat. Rev. Neurol. 8, 329-339 (2012).
49. Lewis S, Dove A, Robbins TW, Barker RA, Owen AM. Cognitive impairments in early Parkinson's disease are accompanied by reductions in activity in frontostriatal neural circuitry. J. Neurosci. 23, 6351-6356 (2003).
50. Albani D, Polito L, Batelli S, De Mauro S et al. The SIRT1 activator resveratrol protects SK-N-BE cells from oxidative stress and against toxicity caused by alpha-synuclein or amyloid-beta (1-42) peptide. J. Neurochem. 110, 1445-1456 (2009).
51. Gelperina S, Maksimenko O, Khalansky A et al. Drug delivery to the brain using surfactant-coated poly(lactide-co-glycolide) nanoparticles: influence of the formulation parameters. Eur. J. Pharm. Biopharm. 74, 157-163 (2010).
52. Garcia-Garcia E, Andrieux K, Gil S, Couvreur P. Colloidal carriers and blood-brain barrier (BBB) translocation: a way to deliver drugs to the brain? Int. J. Pharm. 298, 274-292 (2005).
53. Goppert TM, Muller RH. Polysorbate-stabilized solid lipid nanoparticles as colloidal carriers for intravenous targeting of drugs to the brain: comparison of plasma protein adsorption patterns. J. Drug Targeting 13, 179-187 (2005).
54. Kreuter J. Nanoparticulate systems for brain delivery of drugs. Adv. Drug Deliv. Rev. 47, 65-81 (2001).
55. Kreuter J. Application of nanoparticles for the delivery of drugs to the brain. Int. Congr. Ser. 1277, 85-94 (2005).